FGFR1 and cancer: The relative comparison of IC50s between different cancer cell lines treated with FGFR1 inhibitor (AZD4547, FGFR3861, Foretinib, PD173074, Ponatinib) with a significant difference in primary and metastatic cell lines are shown (Fig. 5c).